IBM, Illumina, Munich Leukemia Laboratory to Develop Genomic Analysis Tech for Leukemia, Lymphoma

NEW YORK (GenomeWeb) – Munich Leukemia Laboratory (MLL) has begun a collaboration with IBM and Illumina to develop a new cognitive technology prototype for providing personalized leukemia and lymphoma treatments.

The project will use IBM’s Watson and MLL will be the first European adopter of the Illumina high-throughput sequencing NovaSeq platform.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
.

Be the first to comment

Leave a Reply

Your email address will not be published.


*